WP
VKTX icon

Woodline Partners’s Viking Therapeutics VKTX Stock Holding History

Woodline Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Hold
302,751
– – 0.04% 493
2026
Q1 		$9.85M Buy
302,751
+719
+0.2% +$23.1K 0.04% 512
2025
Q4 		$10.6M Buy
302,032
+38
+0% +$1.35K 0.04% 446
2025
Q3 		$7.94M Buy
301,994
+797
+0.3% +$23.8K 0.04% 483
2025
Q2 		$7.98M Buy
301,197
+119
+0% +$3.13K 0.04% 471
2025
Q1 		$7.27M Buy
301,078
+207,784
+223% +$6.57M 0.05% 415
2024
Q4 		$3.75M Buy
93,294
+29,475
+46% +$1.68M 0.03% 546
2024
Q3 		$4.04M Sell
63,819
-1,607
-2% -$94.3K 0.03% 415
2024
Q2 		$3.47M Buy
65,426
+118
+0.2% +$7.74K 0.03% 375
2024
Q1 		$5.36M Buy
+65,308
New +$2.91M 0.05% 351

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Woodline Partners's VKTX Position: Q2 2026 in Review

Woodline Partners held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 302,751 shares worth $11.8M. The position accounts for 0.04% of the portfolio, ranked #493.

Woodline Partners first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Woodline Partners held 302,751 shares of Viking Therapeutics worth $11.8M as of Q2 2026.
  • Woodline Partners left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.04% of Woodline Partners's portfolio in Q2 2026, its #493 holding.
  • Woodline Partners first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.